Mark Sheptoff Financial Planning LLC Has $4.94 Million Stake in Abbott Laboratories (NYSE:ABT)

Mark Sheptoff Financial Planning LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,852 shares of the healthcare product maker’s stock after selling 600 shares during the period. Abbott Laboratories comprises approximately 3.0% of Mark Sheptoff Financial Planning LLC’s investment portfolio, making the stock its 8th largest holding. Mark Sheptoff Financial Planning LLC’s holdings in Abbott Laboratories were worth $4,937,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its stake in Abbott Laboratories by 4.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock valued at $3,022,564,000 after buying an additional 1,298,219 shares in the last quarter. Northern Trust Corp lifted its holdings in Abbott Laboratories by 1.5% during the 3rd quarter. Northern Trust Corp now owns 23,016,235 shares of the healthcare product maker’s stock worth $2,229,122,000 after purchasing an additional 343,559 shares in the last quarter. Norges Bank bought a new position in Abbott Laboratories in the 4th quarter worth about $2,115,836,000. Charles Schwab Investment Management Inc. grew its holdings in Abbott Laboratories by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 12,360,908 shares of the healthcare product maker’s stock valued at $1,346,959,000 after buying an additional 207,031 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Abbott Laboratories by 2.4% in the fourth quarter. Fisher Asset Management LLC now owns 9,930,872 shares of the healthcare product maker’s stock worth $1,093,091,000 after buying an additional 236,741 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares in the company, valued at $2,223,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Daniel Gesua Sive Salvadori sold 963 shares of Abbott Laboratories stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $114,115.50. Following the sale, the executive vice president now owns 125,697 shares in the company, valued at $14,895,094.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,884 shares of company stock worth $5,153,916. 1.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of analyst reports. Evercore ISI upped their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Barclays decreased their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, April 22nd. Citigroup dropped their price target on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a research report on Wednesday. Royal Bank of Canada lowered their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Finally, Raymond James reissued a “buy” rating and issued a $124.00 price target on shares of Abbott Laboratories in a research note on Wednesday, April 24th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.60.

Abbott Laboratories Trading Down 0.6 %

Shares of Abbott Laboratories stock traded down $0.67 during trading on Thursday, reaching $104.15. The company’s stock had a trading volume of 3,280,939 shares, compared to its average volume of 5,625,255. The company has a market cap of $181.18 billion, a price-to-earnings ratio of 32.61, a PEG ratio of 2.48 and a beta of 0.76. The firm’s 50-day moving average is $108.59 and its two-hundred day moving average is $109.50. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64. The company has a quick ratio of 1.11, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The firm had revenue of $9.96 billion for the quarter, compared to analysts’ expectations of $9.88 billion. During the same period last year, the firm earned $1.03 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.